A PHASE 3, MULTICENTER, PROSPECTIVE, RANDOMIZED, OPEN-LABEL EFFICACY AND SAFETY STUDY OF INTRAVENOUS BRINCIDOFOVIR VERSUS INTRAVENOUS CIDOFOVIR FOR TREATMENT OF ADENOVIRUS INFECTION IN PEDIATRIC AND ADULT SUBJECTS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (ALLO-HCT)

Registry ID

BCV-PA02

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

SYMBIO PHARMACEUTICALS LTD

Start date

2026-04-13

Last update

2026-01-14

Conditions

• ADENOVIRUS

Related clinical trials

• PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL, WITH CROSS-OVER, OF POSOLEUCEL (ALVR105) FOR THE TREATMENT OF ADENOVIRUS INFECTION IN PEDIATRIC AND ADULT PARTICIPANTS RECEIVING STANDARD OF CARE FOLLOWING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION

View on source registry